Future of InterMune's Esbriet in doubt as US FDA issues complete response letter
This article was originally published in Scrip
Executive Summary
The US FDA has hit InterMune's idiopathic pulmonary fibrosis (IPF) drug candidate Esbriet (pirfenidone) with a complete response letter refusing to approve the drug until the company conducts another clinical trial to support efficacy.